Key result
Cost models based on clinical trials indicate that the use of bivalirudin during PCI offsets most of its own cost through reductions in bleeding and ischemic complications.
Why the study?
Does bivalirudin offset its costs through reduction of complications in patients undergoing PCI?
Population
Patients undergoing percutaneous coronary intervention (PCI)
Design
Review
Authors
Loading...
Bivalirudin may offset its PCI costs via fewer complications; leaves open real-world economic confirmation beyond trial models.
Does bivalirudin offset its costs through reduction of complications in patients undergoing PCI?
Bivalirudin appears to be cost-effective in PCI by offsetting its drug costs through reduced bleeding and ischemic complications.
Anthony Compton (2002) studied Percutaneous coronary intervention (PCI). Bivalirudin was evaluated on Total medical costs. Cost models based on clinical trials indicate that the use of bivalirudin during PCI offsets most of its own cost through reductions in bleeding and ischemic complications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: